3/21
08:06 am
lvtx
LAVA Therapeutics (NASDAQ: LVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
LAVA Therapeutics (NASDAQ: LVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.